Skip to main content

Table 2 Odds ratio of HFNO/MV in univariate binary logistic regression analysis

From: Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COVID-19 disease severity and indicator of the need for mechanical ventilation, ARDS and mortality

  OR (95%CI), p value Nagelkerke R Square N/164
Gender 4.746 (1.833–12.286), = 0.001 .117 164
Age 1.077 (1.040–1.115), < 0.001 .206 164
BMI 1.012 (0.991–1.034), 0.272 .026 152
A.Hypertension 5.111 (2.182–11.974), < 0.001 .146 164
CAD 14.545 (4.190–50.497), < 0.001 .184 164
Diabetes Mellitus 2.600 (0.992–6.817), = 0.052 .034 164
Hyperlipidemia 2.568 (1.111–5.935), = 0.027 .045 164
Atherosclerosis 15.756 (5.623–44.149), < 0.001 .269 164
Renal insufficiency 7.000 (2.228–21.997), = 0.001 .102 164
COPD 3.629 (0.916–14.380), 0.067 .030 164
Inflammatory disease 0.373 (0.083–1.687), = 0.200 .020 164
Malignancy 1.253 (0.425–3.695), = 0.683 .013 164
ACE-I 5.057 (2.046–12.502), < 0.001 .111 164
ARB 1.673(0.597–4.687), 0.327 .009 164
Cortisone 4.121 (1.280–13.270), 0.018 .050 164
Statins 2.769 (1.165–6.581), 0.021 .048 164
ASS/Clopidogrel 3.582 (1.371–9.355), 0.009 .060 164
Horowitz index 0.975 (0.964–0.985), < 0.001 .747 87
SOFA 13.947 (4.162–46.736), < 0.001 .855 164
Maximum SOFA 27.437 (3.411–220.674), = 0.002 .934 164
qSOFA 13.217 (5.508–31.715), < 0.001 .340 164
Lactate 1.238 (1.096–1.399), = 0.001 .351 81
sRAGE Ln 9.509 (4.343–20.819), < 0.001 .472 164
Creatinine 10.894 (2.685–44.202), = 0.001 .306 163
Blood urea nitrogen 1.077 (1.038–1.116), < 0.001 .347 162
Troponin-T 1.201 (1.099–1.312), < 0.001 .569 100
Lactate dehydrogenase 1.009 (1.005–1.012), < 0.001 .369 162
AST 1.013 (1.004–1.022), = 0.005 .188 94
Bilirubin 6.996 (1.573–31.116), = 0.011 .180 89
Iron 0.708 (0.582–0.861), = 0.001 .241 157
Transferrin 0.015 (0.003–0.072), < 0.001 .435 157
Transferrin saturation 0.941 (0.893–0.991), = 0.021 .071 157
Ferritin 1.001 (1.000–1.001), = 0.002 .151 157
CRP 1.034 (1.023–1.046), < 0.001 .657 163
Leucocytes 1.458 (1.236–1.719), < 0.001 .248 164
Haemoglobin 0.676 (0.549–0.831), < 0.001 .148 164
Neutrophils 1.629 (1.342–1.978), < 0.001 .362 164
Lymphocytes 0.029 (0.007–0.129), < 0.001 .345 164
D-Dimer 2.548 (1.542–4.210), < 0.001 .407 112
NT-pro-BNP 1.001 (1.001–1.002), < 0.001 .451 143
CD25 1.002 (1.001–1.003), = 0.001 .330 69
IL-6 1.002 (1.000–1.005), 0.064 .091 84
  1. Table shows odds ratio (OR) of need for high-flow nasal oxygen therapy or mechanical ventilation, calculated using univariate binary logistic regression. Nagelkerke R square reflects the effect size of each variable. Not all variables were determined in outpatients, hence the number of patients analysed was noted (N/164). SOFA score, maximum SOFA score, Horowitz index, Troponin-T and sRAGE Ln have the largest effect size. BMI body mass index, A. Hypertension arterial hypertension, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, SOFA sequential organ failure assessment score, qSOFA quick sequential organ failure assessment score, sRAGE Ln natural log transformed soluble receptor of advanced glycation end product, AST aspartate aminotransferase, CRP C-reactive protein, NT-pro-BNP N-terminal pro b-type Natriuretic Peptide, CD25 soluble interleukin (IL)-2Rα, IL-6 interleukin-6